

МІНІСТЕРСТВО ОХОРОНИ ЗДОРОВ'Я УКРАЇНИ
ДВНЗ "ТЕРНОПІЛЬСЬКИЙ ДЕРЖАВНИЙ МЕДИЧНИЙ
УНІВЕРСИТЕТ ІМЕНІ І.Я. ГОРБАЧЕВСЬКОГО МОЗ УКРАЇНИ"

MINISTRY OF HEALTH OF UKRAINE
I. HORBACHEVSKY TERNOPIL STATE
MEDICAL UNIVERSITY

XXIII МІЖНАРОДНИЙ МЕДИЧНИЙ КОНГРЕС СТУДЕНТІВ ТА МОЛОДИХ ВЧЕНИХ

THE 23d INTERNATIONAL
MEDICAL CONGRESS OF STUDENTS AND YOUNG SCIENTISTS



15-17 КВІТНЯ 2019
APRIL 15-17, 2019

ТЕРНОПІЛЬ
УКРМЕДКНИГА

Відповідальний редактор:

Ректор ДВНЗ «Тернопільський державний медичний університет
імені І.Я. Горбачевського МОЗ України»,
д-р мед. наук, проф. М.М. Корда

Заступники відповідального редактора: проф. І.М. Кліщ

Редакційна колегія:

Асистент: А.І. Дуб, С.В. Кучер

*Студенти: М. Рябокони, О. Косман, Л. Сташишин, І. Стецюк, В. Стецька, А. Брик, П. Левчук,
Ю. Бандрівська, Б. Довгий, О. Болюх, У. Сатурська, Т. Попович, В. Косовська, О. Сопель,
Н. Савчук, Т. Швець, Л. Мазур, О. Пастушина, С. Бандрівська, Ю. Ковальчук*

the samples with ampicillin an average hydrodynamic size of particles was 640 nm (with PVP) or 410 nm (with chitosan). Magnetite NPs, stabilized by PVP and loaded with antibiotic, did not inhibit the growth of test cultures of the standard strain *Candida albicans* ATCC 10231 and clinical *Candida isolate*. When chitosan was used to stabilize NPs, these particles had antifungal activity with minimal fungistatic concentration within the range of 10-5.5 µg/ml. It did not significantly differ for the standard strain and clinical isolate of *Candida albicans*. So, there are reasons to believe that the antifungal effect of composite NPs with ampicillin and chitosan is mainly due to chitosan, which itself has antifungal properties. Such pharmacological agent can provide both the usual antibacterial effect of ampicillin and prevent the development of candidiasis that is very profitable for clinic.

Bortnyk Olha, Pokotylo Olena

**NATIONWIDE TRENDS OF FORMING THE
MEDICINES' REGISTER ACCORDING TO THE
NATIONAL PROGRAM "AFFORDABLE MEDICINES",
2017-2019**

Department of Pharmacy Management, Economics and Technology

Scientific supervisor: PhD, Ass. Prof. O. Pokotylo

I. Horbachevsky Ternopil State Medical University

Ternopil, Ukraine

Nowadays the reform of healthcare is an actual state issue. The Ukrainian government is guided by the European standards. One of that way is the implementation of the Reimbursement Program within successful national drug policy.

The purpose of our work was to conduct a three-year retrospective study of forming medicines' register according to reimbursement policy. The object of our research was assortment of medicinal products (MP) in the number of the international nonproprietary names (INNs) and trade names (TN) included in the "Affordable medicines" program. It was conducted the following methods: logical and systematic, analytical, marketing, comparative analysis and statistical methods, - for realization the aim of research.

According to the results of the study, it was found that during the last three years of the implementation of the national reimbursement program, the number of presented INN increased by 8,7% (by 2 items) and by 23% for the TN (2017 vs 2019). Particularly, it was added one INN - Losartan into the first nosological group of drugs for the treatment of cardiovascular diseases. This medicine was presented with eight trade names (87,0% of which are imported production, in 2018). In addition, it was added one INN - Glibenclamide into the group of drugs for the treatment of diabetes in 2018. This medicine was presented with three TN, all of which are domestic production.

Thus, there is a tendency of increasing the number of medicines' trade names and as well domestic (by 15% in comparison with 2017 vs 2019) as foreign producers (by 50% compared with 2017 vs 2019).

Chonka Helen

**THE PROBLEM OF THE SPREAD DISEASES OF
ORAL MUCOSA AND TREATMENT OPTIONS**

Department of Pharmaceutical Chemistry

Scientific supervisor: dr. pharm., Prof. L.I. Kucherenko

Zaporizhya State Medical University

Zaporozhye, Ukraine

Oral cavity it is the most important organ of human body also this exposed to adverse environmental factors.

So **goal of our research** became problems coverage of oral mucosa diseases in Ukraine. Analyze which pills prescribed for oral mucosa diseases and estimate the range pharmaceutical market of Ukraine.

As **materials and methods** witch we used secondary free information about pills for this diseases

Our results and effects. Analyzes of market research has shown that range of pills for oral mucosa diseases have limited choice and have a selective therapeutic effect. Despite advances in the science of creating new medicines in nowadays, do not satisfy the demand for treatment of this diseases. So it's very important created new treatment pills which based on derivatives of 1,2,4- triazolium and expasession of the domestic pharmaceutical market in Ukraine and thereby improving treatment.

Conclusions. Our evidence show that creation for new treatment pills witch based on derivatives of 1,2,4- triazolium and expasession of the domestic pharmaceutical market in Ukraine stay very important for nowadays.

Established that domestic pharmaceutical market are busy foreign manufactures.

All of this above open new possibilities to created new treatment pills for dentist treatment witch based on derivatives of 1,2,3-triazolium and exprasesion of the domestic pharmaceutical market of Ukraine very important for now days.

Established that domestic pharmaceutical market for oral mucosa diseases busy with foreign manufactures.

All of the above open new posobilites for created new treatment pills for dentist treatment wich based on derivatives of 1,2,4-triazolium and expansion of the domestic pharmaceutical market.

Morenko Mykola, Buchkovskiy Petro

**PASS AND GUSAR COMPUTER PROGRAMS
AS A STARTING POINT FOR DRUG RESEARCH
DEVELOPMENT**

Pharmacology Department

Scientific adviser – doctor of medical sciences, Prof. L.M. Sheremeta

SHEI «Ivano-Frankivsk National Medical University»

Ivano-Frankivsk, Ukraine

For decades pharmaceutical companies has been spending millions of UAH on research and development of new types of drugs. Way the therapeutic compound must went through to become available to end consumer consists of many stages including

<i>Українець Анна</i> СПЕКТР І ЧАСТОТА ВИНИКНЕННЯ ПОБІЧНИХ РЕАКЦІЙ АНТИІНФЕКЦІЙНИХ ЛІКАРСЬКИХ ЗАСОБІВ У ЗАКЛАДАХ ОХОРОНИ ЗДОРОВ'Я ТЕРНОПІЛЬСЬКОЇ ОБЛАСТІ У 2018 РОЦІ	230
<i>Фролова Юлія</i> ВИВЧЕННЯ АКТОПРОТЕКТОРНОЇ АКТИВНОСТІ СЕРЕД ПОХІДНИХ 5-(1Н-ТЕТРАЗОЛ-1-ІЛ)-4-R-3-ТІО(АМІНО)-1,2,4-ТІАЗОЛУ	231
<i>Цикало Тетяна</i> ВИЗНАЧЕННЯ КІЛЬКІСНОГО ВМІСТУ ВІЛЬНИХ ОРГАНІЧНИХ КИСЛОТ В ТРАВІ РИЖІЮ ПОСІВНОГО	231
<i>Чижевська Оксана, Івасюк Ірина, Будняк Лілія</i> ВИЗНАЧЕННЯ ФЕНОЛЬНИХ СПОЛУК У ТРАВІ ТА БУЛЬБАХ СМІКАВЦЯ ЇСТІВНОГО (CYPERUS ESCULENTUS L.)	232
<i>Чорна Валерія, Борсук Сергій</i> ВИВЧЕННЯ ФАРМАЦЕВТИЧНОГО РИНКУ АНКсіОЛІТИЧНИХ ЛІКАРСЬКИХ ЗАСОБІВ	232
<i>Шевченко Олександр, Бідненко Олександр</i> ЩОДО СТВОРЕННЯ КОМБІНОВАНИХ ПРЕПАРАТІВ З ТІОТРИАЗОЛІНОМ	232
<i>Юрчик Віталій, Скринчук Оксана, Слободянюк Людмила</i> ВМІСТ АМІНОКИСЛОТ У КАТРАНУ СЕРЦЕЛИСТОГО ТРАВІ	233
<i>Ajala Olamide Michael</i> ANTIFUNGAL EFFECT OF AMPICILLIN CONJUGATED MAGNETITE NANOPARTICLES	233
<i>Bortnyk Olha, Pokotylo Olena</i> NATIONWIDE TRENDS OF FORMING THE MEDICINES' REGISTER ACCORDING TO THE NATIONAL PROGRAM "AFFORDABLE MEDICINES", 2017-2019	234
<i>Chonka Helen</i> THE PROBLEM OF THE SPREAD DISEASES OF ORAL MUCOSA AND TREATMENT OPTIONS	234
<i>Morenko Mykola, Buchkovskiy Petro</i> PASS AND GUSAR COMPUTER PROGRAMS AS A STARTING POINT FOR DRUG RESEARCH DEVELOPMENT	234
<i>Shkarlat Galyna</i> DEVELOPMENT AND VALIDATION OF GLC/FID-PROCEDURE OF METRONIDAZOLE DETERMINATION BY THE METHODS OF STANDARD	235
<i>Shovkova Oksana</i> DEVELOPMENT AND VALIDATION OF GLC/MS-PROCEDURE OF SECNIDAZOLE DETERMINATION BY THE METHODS OF CALIBRATION CURVE	235
<i>Slabiak Oksana</i> DEVELOPMENT AND VALIDATION OF HPLC/UV-PROCEDURES OF EFAVIRENZ DETERMINATION IN BLOOD	236
•Психіатрія	
<i>Вербіцька Ілона</i> ФІЗІОЛОГІЧНІ ОСОБЛИВОСТІ ФОРМУВАННЯ КОРОТКОЧАСНОЇ І ДОВГОТРИВАЛОЇ ПАМ'ЯТІ У СТУДЕНТІВ ПРАВШІВ ТА ЛІВШІВ	238